NAZIH N. KADRI, M.D.
Osteopathic Medicine at Webster St, Omaha, NE

License number
Nebraska 17993
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
3006 Webster St, Omaha, NE 68131
Phone
(402) 280-4566

Personal information

See more information about NAZIH N. KADRI at radaris.com
Name
Address
Phone
Nazih Kadri
3006 Webster St, Omaha, NE 68131
(402) 980-5971
Nazih Kadri
3006 Webster St, Omaha, NE 68131
(402) 280-4566
Nazih Kadri
4611 96Th St, Omaha, NE 68127
(402) 933-6889
Nazih N Kadri, age 72
15528 Burt St, Omaha, NE 68154

Professional information

Nazih N Kadri Photo 1

Dr. Nazih N Kadri - MD (Doctor of Medicine)

Hospitals:
3006 Webster St, Omaha 68131
Alegent Creighton Health Bergan Mercy Medical Center
7500 Mercy Rd, Omaha 68124
3006 Webster St, Omaha 68131
Alegent Creighton Health Bergan Mercy Medical Center
7500 Mercy Rd, Omaha 68124
Education:
Medical Schools
American University Of Beirut, Faculty Of Medicine
Graduated: 1980


Nazih N Kadri Photo 2

Nazih N Kadri, Onawa IA

Specialties:
Cardiologist
Address:
1110 17Th St, Onawa, IA 51040
3006 Webster St, Omaha, NE 68131
Education:
American University of Beirut, Faculty of Medicine - Doctor of Medicine
University of Wisconsin Hospital & Clinics - Fellowship - Cardiology
Cleveland Clinic Hospital - Residency - Internal Medicine
American University of Beirut Medical Center - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine), American Board of Internal Medicine Sub-certificate in Clinical Cardiac Electrophysiology (Internal Medicine)


Nazih Kadri Photo 3

Method For Treating Neurocardiogenic Syncope

US Patent:
5706829, Jan 13, 1998
Filed:
Jun 6, 1996
Appl. No.:
8/660798
Inventors:
Nazih Najih Kadri - Omaha NE
Assignee:
Creighton University - Omaha NE
International Classification:
A61B 1900
US Classification:
128898
Abstract:
The present invention relates to methods for treating neurocardiogenic syncope. The method involves administering to a patient an effective amount of a compound having the formula: ##STR1## wherein R. sub. 1, R. sub. 2 and R. sub. 5 are each selected from the group consisting of hydrogen and lower alkyl; and R. sub. 3 and R. sub. 4 are each selected from the group consisting of hydrogen, halogen, lower alkyl, nitro, amino, trifluoromethyl, and lower acylamino; at least one of R. sub. 3 and R. sub. 4 being a nitrogen containing group, or a pharmaceutically acceptable salt thereof.